RT Journal Article
SR Electronic
T1 Effect of experimental hookworm infection on insulin resistance in people at risk of Type 2 Diabetes: a randomized, placebo-controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.16.23287372
DO 10.1101/2023.03.16.23287372
A1 Pierce, Doris R.
A1 McDonald, Malcolm
A1 Merone, Lea
A1 Becker, Luke
A1 Thompson, Fintan
A1 Lewis, Chris
A1 Field, Matthew A.
A1 Rahman, Tony
A1 Croese, John
A1 Loukas, Alex
A1 McDermott, Robyn
A1 Giacomin, Paul R.
YR 2023
UL http://medrxiv.org/content/early/2023/03/20/2023.03.16.23287372.abstract
AB The reduced prevalence of insulin resistance and type 2 diabetes (T2D) in countries with endemic parasitic worm infections suggests a protective role for worms against metabolic disorders, however clinical evidence has been non-existent. This 2-year randomized controlled trial of hookworm infection in 40 people at risk of T2D involved treatment with either 20 or 40 Necator americanus third-stage larvae (L3) or Placebo. Primary outcome was safety, with homeostatic model assessment of insulin resistance (HOMA-IR), fasting blood glucose (FBG), and body mass being the key metabolic outcomes. Adverse events were more frequent in hookworm-treated participants, where 44% experienced transient gastrointestinal symptoms. FBG and HOMA-IR were significantly lowered in both hookworm-treated groups at 1-year, and body mass was significantly lowered after L3-20 treatment at 2-years. Overall, hookworm infection was well tolerated in people at risk of T2D, and were associated with improved insulin resistance, warranting further exploration of the benefits of hookworms on metabolic health.Competing Interest StatementP.R.G and A.L are founders and shareholders of Macrobiome Therapeutics, which is developing hookworm-derived proteins as drugs for treating inflammatory conditions.Clinical TrialACTRN12617000818336Funding StatementThe work was funded by the Far North QLD Hospital Foundation (PG, RM, AL), Australian Institute of Tropical Health and Medicine (RM, PG, AL), Australian National Health and Medical research Council (NHMRC) Senior Principal Research Fellowship (AL), Program Grant (AL), Advance Queensland Fellowship (PG) and an Australian Research Training Program Stipend (DP). Funders had no role in the design or conduct of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The James Cook University Human Research Ethics Committee of James Cook University, Australia gave ethical approval for this work, designated C26I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors